Meridian Bioscience

Meridian Bioscience EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Meridian Bioscience (VIVO) as of Oct 27, 2026 is 11.03 %. In the previous year, EBIT CAGR (5 Year) was 11.03 % — a change of 0.00% (lower).

EBIT CAGR 5Y

11.03 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Meridian Bioscience is 2022 11.03 % . EBIT CAGR (5 Year) of Meridian Bioscience was 2021 11.03 % . It decreases by 0.00% lower compared to the previous year.

The Meridian Bioscience EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2015
11.03 USD
Jan 1, 2016
11.03 USD
Jan 1, 2017
11.03 USD
Jan 1, 2018
11.03 USD
Jan 1, 2019
11.03 USD
Jan 1, 2020
11.03 USD
Jan 1, 2021
11.03 USD
Jan 1, 2022
11.03 USD
The Meridian Bioscience EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
11.03 %0.00%
11.03 %0.00%
11.03 %0.00%
11.03 %0.00%
11.03 %0.00%
11.03 %0.00%
11.03 %0.00%
11.03 %0.00%
11.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

EBIT CAGR (5 Year) of Meridian Bioscience is 11.03 % in 2022.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Meridian Bioscience

All Key Metrics — Meridian Bioscience